

DELflex

80%
Success in
identifying
functional
hits

Cost-effective,
flexible, and
scalable
solution for hit
identification.

Accelerate Small Molecule Discovery with Unmatched Efficiency

Designed for researchers in emerging pharma and biotech, X-Chem's DELflex partnership model provides access to our world-leading DNA-encoded library (DEL) screening platform. With DELflex, you can rapidly explore billions of small molecules, leveraging cutting-edge technology and expert guidance to streamline drug discovery with speed, precision, and flexibility.

Key Benefits

Feature	DELflex	Other companies
Number of Compounds	> 15 billion non-covalent compounds > 115 billion covalent compounds	Fewer compounds with less diversity
Data Quality	All enriched compounds clustered and reported to partners	More noise and less annotations
Customization	Target-specific, tailored screen	Limited expert guidance
Expert Support	Full support from X-Chem scientists	Minimal or no support
Transparency	Structures revealed with SAR	Structures disclosed with a fee

What Challenges DELflex Solves

- › Identification of novel small-molecule modulators for challenging targets
- › Inconsistent or non-actionable results
- › Elucidating modes of actions from identified hits
- › Flagging of promiscuous binders
- › Difficulty of prioritizing compounds


Interested in
exclusive license
to confirmed hit
compounds?
Check our
DELcore model.



Flexible Partnership Model

As the pioneer of DEL technology, X-Chem brings over 15 years of expertise on our world-leading DEL platform. We understand the importance of flexibility in financial and partnership terms, so we create DELflex to ensure partners can fully leverage our capabilities without substantial upfront investment.

Our Unique Advantages



Drug-like Molecular Properties

Our DEL libraries are specifically designed to prioritize drug-like molecular properties, ensuring that identified hits are not only potent but also have the ideal characteristics for further development, such as favorable ADMET profiles



Fast Chemistry Follow-up (Add-on)

Partners receive timely and efficient synthesis of selected compounds for validation, ensuring an accelerated progression from initial hits to optimized lead candidates.



SAR Trends & Mechanistic Insights

We provide more than just hits. By analyzing the data, we deliver actionable intelligence that guides further compound optimization and identifies key binding modes.



Expert Guidance & Collaborative Discovery

As a partner, you gain access to X-Chem's team of scientists. Our experts work alongside you to interpret screening results, develop actionable strategies, and guide your project toward success.

X-Chem is the partner you need to unlock exponential possibilities in your small molecule drug discovery.

Find Your Next Candidate With X-Chem

ABOUT X-CHEM

X-Chem, Inc. is the leader in small molecule discovery science, providing pharmaceutical and biotech companies a complete, seamless solution for screening, hit validation and lead optimization. As pioneers of DNA-encoded chemical library (DEL) technology, the company leverages its market-leading DEL platform to discover novel small molecule leads against challenging, high-value therapeutic targets. In-house lead optimization services enable clients to progress their compounds directly for even higher quality outputs. Our expertise in medicinal chemistry, custom synthesis and scale-up process chemistry enables us to support all aspects of drug discovery, supporting lead optimization through candidate identification.